The International Collaboration on Cosmetics Safety enters a new chapter with the appointment of its 2026 Board officers, reinforcing its global commitment to advancing animal-free approaches in cosmetics safety science at a time of rapid regulatory and scientific change.
The International Collaboration on Cosmetics Safety (ICCS) has confirmed its Board officers for 2026, following elections held during the organization’s December 2025 Board meeting. The announcement marks a significant milestone for the relatively young global initiative, which continues to position itself at the forefront of efforts to replace animal testing in cosmetics safety assessment with scientifically robust, human-relevant alternatives. The newly elected leadership reflects both continuity and growing maturity within ICCS, as the organization builds on a year of substantial progress and looks ahead to expanding its impact across regulatory, scientific, and industry communities worldwide.
ICCS works at the nexus of science, policy, and collective action, uniting a broad array of stakeholders who pursue a shared mission: advancing the worldwide integration and recognition of animal-free safety science for cosmetics and their components. The appointment of the 2026 Board officers highlights the organization’s commitment to preserving a strategic trajectory while navigating an increasingly intricate global environment, where expectations surrounding ethical research, scientific robustness, and regulatory coherence are continually shifting.
Ongoing leadership stability and broad international representation
The 2026 Board leadership unites senior representatives from the cosmetics, consumer goods, and regulatory advocacy fields, underscoring the multi‑stakeholder foundation that has characterized ICCS since its beginning. Stéphane Dhalluin, Ph.D., DABT, Global Head of Human & Environmental Safety Evaluation at L’Oréal, has been chosen once again to serve as Chair of the Board of Directors. His renewed mandate reflects sustained trust in a leadership style that prioritizes scientific rigor, international collaboration, and effective dialogue with regulatory bodies.
Serving alongside him as Vice Chair is Darren Praznik, President and Chief Executive Officer of Cosmetics Alliance Canada, whose long-standing work in industry advocacy and regulatory engagement provides a strong regional and policy-driven outlook. The role of Secretary will be fulfilled by Heike Scheffler, Ph.D., Safety Advocacy and Regulatory Toxicology Director for Global Product Stewardship in Beauty and Oral Care at Procter & Gamble, bringing broad expertise in regulatory toxicology and global product safety systems. Michael Southall, Ph.D., Senior Director and Head of Global Toxicology and Clinical Safety within Medical Clinical & Safety Sciences at Kenvue, has been appointed Treasurer, offering substantial leadership experience in toxicology and governance.
Acting collectively, the officers make up a Board leadership team whose experience extends across multinational corporations, industry groups, and regulatory science, strengthening ICCS’ role as a neutral forum for cooperation rather than an advocate for any particular sector. This equilibrium underpins the organization’s credibility, especially as it works to shape regulatory perspectives and promote alignment on animal-free safety approaches.
Driving the progress of animal-free science through collective collaboration
At the core of ICCS’ mission lies the conviction that animal-free safety assessment approaches, when fully refined and validated, are not only ethically sound but also offer superior scientific performance. Since its establishment in early 2023, ICCS has sought to show that non-animal methods can deliver dependable and meaningful data to safeguard both human health and the environment. The confirmation of the 2026 Board officers arrives at a time when this message is gaining momentum, bolstered by concrete achievements and increasing engagement from regulators across the globe.
During 2025, ICCS delivered a series of initiatives that strengthened its scientific foundation and expanded its influence. Among these was the release of a Best Practice Guidance document, designed to provide clarity and consistency in the application of animal-free safety assessment approaches. This guidance aimed to bridge gaps between scientific innovation and regulatory expectations, offering a practical framework that stakeholders could reference when developing or evaluating non-animal data.
In parallel, ICCS supported the development of new methodologies aligned with next generation risk assessment (NGRA), an evolving paradigm that integrates advanced in vitro, in silico, and exposure-based approaches. These methodologies are increasingly viewed as essential to modern toxicology, offering the potential for more human-relevant insights while reducing reliance on animal testing. ICCS’ involvement in this space reflects its commitment to advancing not only ethical outcomes but also scientific excellence.
Equally important has been the organization’s emphasis on dialogue. Throughout 2025, ICCS engaged extensively with regulators, scientists, and policymakers across multiple regions, contributing to discussions on how animal-free data can be interpreted and accepted within existing regulatory frameworks. These conversations have been instrumental in building shared understanding and trust, particularly in jurisdictions where regulatory acceptance of non-animal methods is still developing.
A defining turning point in cosmetics safety oversight
The appointment of the 2026 Board officers takes place against a backdrop of significant change in global cosmetics regulation. Many markets are reassessing long-standing testing requirements, responding to public expectations, scientific advances, and international policy trends. In this context, organizations like ICCS play a critical role in helping align innovation with regulation, ensuring that progress is both credible and sustainable.
ICCS leadership has long stressed that advancing animal-free safety science cannot happen through fragmented initiatives; rather, it demands synchronized efforts involving industry, academia, regulators, and civil society. This approach is mirrored in the Board’s makeup, which unites leaders who grasp the technical, regulatory, and organizational aspects required to drive meaningful change.
Statements from ICCS leadership following the elections conveyed a blend of confidence and pragmatism, noting the progress achieved in recent years while recognizing that substantial challenges persist. They emphasized that gaining broad regulatory acceptance for animal-free methods will still demand sustained research investment, open data sharing, and continuous collaboration with authorities to address valid concerns regarding reliability, practical relevance, and the safeguarding of public health.
The re-elected Chair emphasized the importance of leveraging ICCS’ global, multi-stakeholder model to close the gap between innovation and regulation. This approach aims to ensure that advances in animal-free science are not confined to research settings but translated into practical tools that regulators can trust and apply consistently.
Strengthening foundations for long-term impact
As ICCS looks ahead to 2026 and beyond, the organization is focused on consolidating its achievements while expanding its reach. The newly confirmed Board leadership is expected to play a central role in shaping priorities that balance scientific ambition with practical implementation. This includes identifying areas where additional guidance or consensus-building is needed, supporting the validation and communication of new methodologies, and fostering international alignment to reduce fragmentation in regulatory requirements.
Education continues to be a central pillar of ICCS’ strategy, with the organization striving to offer accessible, science‑grounded materials and spaces for dialogue that help clarify the principles of animal‑free safety science and support well‑informed choices. This effort becomes especially vital in a field where misunderstandings or uneven levels of expertise can hinder advancement, even when the science itself is robust.
The organization’s structure, which includes market-leading cosmetics and ingredient manufacturers, trade and research associations, and animal protection organizations, positions it uniquely to address these challenges. This diversity of perspectives helps ensure that discussions remain grounded, balanced, and focused on shared goals rather than narrow interests.
Based in New York, ICCS remains active as a worldwide initiative, underscoring the global character of cosmetic innovation and regulatory oversight. As products and their ingredients circulate internationally, coordinated standards and mutual acknowledgment of safety practices become ever more crucial. By working collaboratively, ICCS aims to support this alignment, minimize redundant efforts, and strengthen confidence in animal-free science across the globe.
In confirming its 2026 Board officers, ICCS signals both stability and forward momentum. The leadership team brings continuity from a year marked by concrete achievements, alongside the experience and perspective needed to navigate the next phase of change. As scientific innovation accelerates and regulatory expectations evolve, the organization’s role as a convener and catalyst for animal-free cosmetics safety science is set to become even more relevant.
Ultimately, the significance of the 2026 Board elections lies not only in the individuals appointed, but in what their leadership represents: a sustained commitment to collaboration, scientific integrity, and the responsible advancement of alternatives to animal testing. For ICCS and its stakeholders, the coming years offer an opportunity to translate vision into lasting impact, shaping the future of cosmetics safety in a way that aligns ethics, science, and global public trust.
